Endocyte (ECYT) 10-Q 8 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 04, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'ENDOCYTE INC	'
Entity Central Index Key	'0001235007	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Trading Symbol	'ECYT	'
Entity Common Stock, Shares Outstanding	'	36,143,594
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Assets	'	'
Cash and cash equivalents	$51,245,919	$33,996,866
Short-term investments	59,908,749	141,840,823
Receivables	8,332,938	5,689,067
Prepaid expenses	3,823,499	2,799,883
Other assets	603,118	498,203
Total current assets	123,914,223	184,824,842
Long-term investments	48,037,144	25,540,649
Property and equipment, net	3,440,872	3,166,905
Other noncurrent assets	179,314	546,313
Total assets	175,571,553	214,078,709
Liabilities and Stockholders’ Equity	'	'
Accounts payable	5,001,092	3,647,967
Accrued wages and benefits	2,263,001	2,426,534
Accrued clinical trial expenses	3,605,952	2,486,967
Accrued expenses	1,673,560	1,902,910
Deferred revenue	58,105,942	51,993,200
Current portion of other liabilities	16,870	12,647
Total current liabilities	70,666,417	62,470,225
Other liabilities, net of current portion	38,529	42,065
Deferred revenue, net of current portion	15,457,733	51,993,141
Total liabilities	86,162,679	114,505,431
Stockholders’ equity:	'	'
Common stock: $0.001 par value, 100,000,000 shares authorized; 35,919,019 and 36,125,397 shares issued and outstanding at December 31, 2012 and September 30, 2013	36,126	35,919
Additional paid-in capital	260,374,376	255,356,888
Accumulated other comprehensive income	20,955	72,749
Retained deficit	-171,022,583	-155,892,278
Total stockholders’ equity	89,408,874	99,573,278
Total liabilities and stockholders’ equity	$175,571,553	$214,078,709

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	36,125,397	35,919,019
Common stock, shares outstanding	36,125,397	35,919,019

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue:	'	'	'	'
Collaboration revenue	$16,599,294	$12,414,684	$47,596,716	$20,227,649
Operating expenses:	'	'	'	'
Research and development	13,500,848	9,930,766	44,366,512	25,153,659
General and administrative	6,142,782	3,814,991	18,610,213	10,103,692
Total operating expenses	19,643,630	13,745,757	62,976,725	35,257,351
Loss from operations	-3,044,336	-1,331,073	-15,380,009	-15,029,702
Other income (expense), net:	'	'	'	'
Interest income	111,300	96,459	377,653	137,497
Interest expense	-548	-891	-1,991	-628,215
Other income (expense), net	-107,574	-3,861	-125,958	-922,744
Net loss	-3,041,158	-1,239,366	-15,130,305	-16,443,164
Net loss per share - basic and diluted (in dollars per share)	($0.08)	($0.03)	($0.42)	($0.46)
Items included in other comprehensive income (loss):	'	'	'	'
Unrealized gain (loss) on foreign currency translation	3,419	1,544	-17,831	2,624
Unrealized gain (loss) on available-for-sale securities	105,088	114,855	-33,963	70,324
Other comprehensive income (loss)	108,507	116,399	-51,794	72,948
Comprehensive loss	($2,932,651)	($1,122,967)	($15,182,099)	($16,370,216)
Weighted-average number of common shares used in net loss per share calculation - basic and diluted (in shares)	36,077,440	35,881,112	36,000,242	35,841,116

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]
Balances at Dec. 31, 2012	$99,573,278	$35,919	$255,356,888	$72,749	($155,892,278)
Balances (in shares) at Dec. 31, 2012	'	35,919,019	'	'	'
Exercise of stock options	611,856	173	611,683	0	0
Exercise of stock options (in shares)	'	172,584	'	'	'
Exercise of warrants	0	34	-34	'	'
Exercise of warrants (in shares)	'	33,794	'	'	'
Stock-based compensation	4,405,839	0	4,405,839	0	0
Net loss	-15,130,305	0	0	0	-15,130,305
Unrealized loss on foreign currency translation	-17,831	0	0	-17,831	0
Unrealized loss on securities	-33,963	0	0	-33,963	0
Balances (unaudited) at Sep. 30, 2013	$89,408,874	$36,126	$260,374,376	$20,955	($171,022,583)
Balances (unaudited) (in shares) at Sep. 30, 2013	'	36,125,397	'	'	'

CONSDENSED_CONSOLIDATED_STATEM

CONSDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities	'	'
Net loss	($15,130,305)	($16,443,164)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'
Depreciation	489,045	244,004
Stock-based compensation expense	4,405,839	2,248,354
Accretion of bond discount	895,782	564,690
Non cash interest expense	0	73,915
Loss on disposal of equipment	1,778	0
Loss on debt extinguishment	0	992,281
Change in operating assets and liabilities:	'	'
Receivables	5,795,745	-5,738,330
Prepaid expenses and other assets	1,237,111	-313,968
Accounts payable	-390,851	-489,281
Accrued interest, wages, benefits and other liabilities	486,726	1,549,308
Deferred revenue	-38,994,877	109,229,320
Net cash provided by (used in) operating activities	-41,204,007	91,917,129
Investing activities	'	'
Purchases of property and equipment	-646,799	-1,626,280
Purchases of investments	-109,123,099	-243,336,342
Proceeds from sale of investments	167,628,933	141,595,642
Net cash provided by (used in) investing activities	57,859,035	-103,366,980
Financing activities	'	'
Repayment of long-term borrowings	0	-13,544,175
Proceeds from the exercise of stock options	611,856	367,596
Net cash provided by (used in) financing activities	611,856	-13,176,579
Effect of exchange rate	-17,831	2,624
Net increase (decrease) in cash and cash equivalents	17,249,053	-24,623,806
Cash and cash equivalents at beginning of period	33,996,866	61,352,483
Cash and cash equivalents at end of period	$51,245,919	$36,728,677

Nature_of_Business_and_Organiz

Nature of Business and Organization	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1. Nature of Business and Organization
	Endocyte, Inc. (the “Company”) is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The Company uses its proprietary technology to create novel small molecule drug conjugates (“SMDCs”), and companion imaging diagnostics. The SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with a highly active drug at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The Company is also developing companion imaging diagnostics for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
	The Company has two wholly-owned subsidiaries, Endocyte Europe B.V. and Endocyte Europe G.m.b.H, which have been formed to assist with the administration of the pending applications with the European Medicines Agency (“EMA”) and pre-commercial planning activities in Europe.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2. Significant Accounting Policies
	Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated. The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2013 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission.
	Segment Information
	Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company is performing clinical trials globally and has established subsidiaries in The Netherlands and Switzerland to assist in the administration of pending applications with the EMA and pre-commercial planning activities in Europe. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager.
	Investments
	Investments consist primarily of investments in U.S. Treasuries, U.S. Government agency obligations and corporate debt securities, which could also include commercial paper, that are maintained by an investment manager. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, Investments — Debt and Equity Securities (“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expense over the term of the security.
	Revenue Recognition
	The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605, Revenue Recognition (“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25, Multiple-Element Arrangements. Effective January 1, 2011, the Company adopted an accounting standard update that amends the guidance on accounting for arrangements with multiple deliverables. Pursuant to the new standard, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables.
	Upfront payments for licensing the Company's intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue in the balance sheet and are recognized in a manner consistent with the final deliverable. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered.
	In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred.
	Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e. not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone.
	Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company's products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and the collaborator will share profit, the revenue will be recorded in the period earned.
	Research and Development Expenses
	Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging diagnostics and include salaries, supplies, and expenses for clinical trials. The Company records accruals for clinical trial expenses based on the estimated amount of work completed. The Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations.
	Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20, Research and Development Arrangements. Upfront payments made in connection with business development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development and are expensed over the service period based upon the level of services provided. As of September 30, 2013, the Company had approximately $3.2 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets.
	Stock-Based Compensation
	The Company accounts for its stock options pursuant to ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the recognition of the fair value or calculated value for nonpublic entities, of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted to employees at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant. The Company has issued restricted stock units (“RSUs”) for which stock-based compensation expense will be recognized when the Company determines it is probable that the performance conditions will be achieved. The Company used the calculated value to measure its stock-based compensation prior to its initial public offering. The Company recognizes compensation cost based on the grant-date value estimated in accordance with the provisions of ASC 718.
	Net Loss Per Share
	Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants and RSUs are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.
	The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net loss per share computations. The calculation below provides net loss, weighted-average common shares outstanding, and the resultant net loss per share on both a basic and diluted basis for the three and nine months ended September 30, 2012 and 2013.
	Historical net loss per share
		Three Months Ended September 30,					Nine Months Ended September 30,
		2012			2013		2012		2013
	Numerator:
	Net loss	$	-1,239,366		$	-3,041,158	$	-16,443,164	$	-15,130,305
	Denominator:
	Weighted-average common shares outstanding		35,881,112			36,077,440		35,841,116		36,000,242
	Basic and diluted net loss per share	$	-0.03		$	-0.08	$	-0.46	$	-0.42
	Common stock equivalents
	As of September 30, 2012 and 2013, the following number of potential common stock equivalents were outstanding:
		As of September 30,
		2012		2013
	Outstanding common stock options	3,876,968		5,157,967
	Outstanding warrants	133,968		69,294
	Outstanding RSUs	273,988		271,062
	Total	4,284,924		5,498,323
	These common stock equivalents were excluded from the determination of diluted net loss per share due to their anti-dilutive effect on earnings.

New_Accounting_Pronouncements

New Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
Accounting Changes and Error Corrections [Abstract]	'
Accounting Changes and Error Corrections [Text Block]	'
	3. New Accounting Pronouncements
	Recently Adopted Accounting Standards
	In January 2013, the FASB issued Accounting Standards Update (“ASU”) No. 2013-01, Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities, an update to ASC Topic 210, Balance Sheet. This update clarifies that the scope of Update 2011-11, Disclosures about Offsetting Assets and Liabilities, applies to derivatives accounted for in accordance with ASC Topic 815, Derivatives and Hedging, including bifurcated embedded derivatives, repurchase agreements and reverse repurchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with ASC Section 210-20-45 or ASC Section 815-10-45 or subject to an enforceable master netting arrangement or similar agreement . This update became effective for the Company for the fiscal year beginning on January 1, 2013 and was to be applied retrospectively for all comparative periods presented. The adoption of this guidance had no impact on the Company’s condensed consolidated financial statements.
	In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, an update to ASC Topic 220, Comprehensive Income. This amendment requires entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. Entities are required to present, either on the face of the statement where net income is present or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about those amounts. This update became effective for the Company for the fiscal year beginning January 1, 2013 and was applied prospectively. The adoption did not have a material impact on the Company’s condensed consolidated financial statements.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, an update to ASC Topic 740, Income Taxes.  This amendment provides clarification regarding the presentation of an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. Under this new standard, the liability related to an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset if available under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position. Otherwise, the unrecognized tax benefit should be presented in the financial statements as a separate liability. The assessment is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date. The provisions of the new standard are effective on a prospective basis beginning in 2014 for annual and interim reporting periods. Early adoption is permitted. This update will be effective for the Company beginning January 1, 2014. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

Other_Comprehensive_Income_Los

Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2013
Other Comprehensive Income (Loss), Tax [Abstract]	'
Other Comprehensive Income (Loss) [Text Block]	'
	4. Other Comprehensive Income (Loss)
	The accumulated balances related to each component of other comprehensive income (loss) were as follows:
		Foreign Currency		Unrealized Net		Accumulated
		Translation Gains		Gains (Losses)		Other
		(Losses)		on		Comprehensive
				Securities		Gains
						(Losses)
	Balance at December 31, 2012	$	-5,011	$	77,760	$	72,749
	Unrealized loss		-17,831		-29,047		-46,878
	Net amount reclassified to net loss		—		-4,916		-4,916
	Other comprehensive loss		-17,831		-33,963		-51,794
	Balance at September 30, 2013	$	-22,842	$	43,797	$	-20,955
	The assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows, which results in translation adjustments being made in stockholders’ equity rather than to net loss.
	Reclassifications Out of Accumulated Other Comprehensive Loss
	For the Nine Months Ended September 30, 2013
		Amount
		Reclassified from
		Accumulated
		Other
		Comprehensive
		Loss
	Details about Accumulated Other	Three		Nine Months		Affected Line Item in the
	Comprehensive Loss Components	Months		Ended		Condensed Consolidated
		Ended		September		Statements of Operations and
		September		30, 2013		Comprehensive Loss
		30, 2013
	Unrealized Net Gains on Securities	$	536	$	4,916	Other income (expense)
	Total Reclassifications for the period	$	536	$	4,916

Investments

Investments	9 Months Ended
	Sep. 30, 2013
Investments, Debt and Equity Securities [Abstract]	'
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	'
	5. Investments
	The Company applies the fair value measurement and disclosure provisions of ASC Topic 820, Fair Value Measurements (“ASC 820”) which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Investments consist primarily of investments with original maturities greater than three months, but no longer than 24 months when purchased.
	ASC 820 establishes a three-level valuation hierarchy for fair value measurements. These valuation techniques are based upon the transparency of inputs (observable and unobservable) to the valuation of an asset or liability as of the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy:
	Level 1 — Valuation is based on quoted prices for identical assets or liabilities in active markets.
	Level 2 — Valuation is based on quoted prices for similar assets or liabilities in active markets, or other inputs that are observable for the asset or liability, either directly or indirectly, for the full term of the financial instrument.
	Level 3 — Valuation is based upon other unobservable inputs that are significant to the fair value measurement.
	The fair value of the Company’s fixed income securities is based on a market approach using quoted market values.
	The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2012:
	Description	Cost		Level 1		Level 2		Fair Value
								(Carrying
								Value)
	Cash
	Cash	$	5,227,208	$	5,227,208	$	—	$	5,227,208
	Cash equivalents
	Money market funds		28,769,658		28,769,658		—		28,769,658
	Cash and cash equivalents	$	33,996,866	$	33,996,866	$	—	$	33,996,866
	Short-term investments (due within 1 year)
	U.S. government treasury obligations	$	10,049,323	$	10,053,393	$	—	$	10,053,393
	U.S. government agency obligations		89,824,358		89,847,365		—		89,847,365
	Corporate obligations		41,905,867		—		41,940,065		41,940,065
	Total Short-term investments	$	141,779,548	$	99,900,758	$	41,940,065	$	141,840,823
	Long-term investments (due after 1 year through 2 years)
	U.S. government treasury obligations	$	5,024,697	$	5,030,699	$	—	$	5,030,699
	U.S. government agency obligations		17,455,606		17,463,067		—		17,463,067
	Corporate obligations		3,043,860		—		3,046,883		3,046,883
	Total Long-term investments	$	25,524,163	$	22,493,766	$	3,046,883	$	25,540,649
	The following table summarizes the fair value of cash and cash equivalents and investments as of September 30, 2013:
	Description	Cost		Level 1		Level 2		Fair Value
								(Carrying
								Value)
	Cash
	Cash	$	10,416,113	$	10,416,113	$	—	$	10,416,113
	Cash equivalents
	Money market funds		40,829,806		40,829,806		—		40,829,806
	Cash and cash equivalents	$	51,245,919	$	51,245,919	$	—	$	51,245,919
	Short-term investments (due within 1 year)
	U.S. government treasury obligations	$	15,023,419		15,035,200		—		15,035,200
	U.S. government agency obligations		16,171,793		16,184,311		—		16,184,311
	Corporate obligations		28,678,553		—		28,689,238		28,689,238
	Total Short-term investments	$	59,873,765		31,219,511		28,689,238		59,908,749
	Long-term investments (due after 1 year through 2 years)
	U.S. government treasury obligations	$	—		—		—		—
	U.S. government agency obligations		35,116,060		35,131,581		—		35,131,581
	Corporate obligations		12,912,265		—		12,905,563		12,905,563
	Total Long-term investments	$	48,028,325		35,131,581		12,905,563		48,037,144
	All securities held at September 30, 2013, were classified as available-for-sale as defined by ASC 320.
	Total unrealized gross gains were $71,936 and $72,526 for the nine months ended September 30, 2012 and 2013, respectively. Total unrealized gross losses were $2,158 and $28,729 for the nine months ended September 30, 2012 and 2013, respectively. The Company does not consider any of the unrealized losses to be other-than-temporary impairments because the Company has the intent and ability to hold investments until they recover in value.

Collaborations

Collaborations	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborative Arrangement Disclosure [Text Block]	'
	6. Collaborations
	Merck Collaboration Agreement
	In April 2012, the Company entered into a worldwide collaboration agreement with Merck Sharp & Dohme Research GmbH, a Subsidiary of Merck & Co, Inc. (“Merck”) regarding the development and commercialization of vintafolide. The agreement grants Merck worldwide rights to develop and commercialize vintafolide and the right to use etarfolatide, the companion imaging diagnostic for vintafolide. The Company received a $120.0 million non-refundable upfront payment and a $5.0 million milestone payment in 2012 and is eligible for additional milestone payments of up to $875.0 million based on the successful achievement of development, regulatory and commercialization goals for vintafolide in a total of six different cancer indications. In addition, in the event there is regulatory approval and launch of vintafolide, the Company will split U.S. earnings under the collaboration arrangement on a 50/50 basis with Merck and will receive a double-digit percentage royalty on sales of the product in the rest of the world. The Company has retained the right (which it can opt out of) to co-promote vintafolide with Merck in the U.S. and Merck has the exclusive right to promote vintafolide in the rest of the world. The Company will be responsible for the majority of funding and completion of the ongoing Phase 3 PROCEED clinical trial of vintafolide for the treatment of patients with platinum resistant ovarian cancer. The Company is responsible for the execution of the Phase 2b TARGET trial of vintafolide for the treatment of second line non-small cell lung cancer. Merck is responsible for the costs of the TARGET trial and for all other development activities and costs and will have all decision rights with respect to the development and commercialization of vintafolide. The Company will remain responsible for the development, manufacture and commercialization worldwide of etarfolatide.
	For revenue recognition purposes, the Company viewed the collaboration with Merck as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company evaluated whether the delivered elements under the arrangement have value on a stand-alone basis and whether objective and reliable evidence of fair value of the undelivered element exists. Deliverables that do not meet these criteria are not evaluated separately for the purpose of revenue recognition. For a single unit of accounting, payments received are recognized in a manner consistent with the final deliverable. The Company has determined that the deliverables related to the collaboration with Merck, including the licenses granted to Merck, as well as the Company performance obligations to provide various research and development services, will be accounted for as a single unit of account. This determination was made because the successful development of the therapeutic drug, vintafolide, is dependent on the companion diagnostic, etarfolatide, to select patients who are most likely to receive the most benefit from vintafolide. Given the nature of the combined benefit of the companion diagnostic and the therapeutic drug, the ongoing research and development services to be provided by the Company are essential to the overall arrangement as the Company has significant knowledge and technical know-how that is important to realizing the value of the licenses granted. The performance period over which the revenue will be recognized continues from the date of execution of the agreement through the end of 2014, when the Company expects to be completed with the various trials that are specified in the collaboration agreement and the Company’s performance obligations will be completed. The Company will continue to review the timing of when the various trials will be completed in order to assess that the estimated performance period over which the revenue is to be recognized is appropriate. Any significant changes in the timing of the performance period could result in a change in the revenue recognition period.
	The Company will recognize the non-refundable $120.0 million upfront payment and funding from the research and development services on a straight-line basis over the performance period. The Company recognized approximately $16.6 million and $47.6 million of collaboration revenue during the three and nine month periods ended September 30, 2013, respectively, and had deferred revenue related to the collaboration of approximately $73.6 million at September 30, 2013. As future research and development services are performed and become billable, the Company will utilize a cumulative catch-up approach for purposes of recognizing the consideration on a straight-line basis. Though accounted for as a single unit of account for presentation purposes, the Company has made an allocation of revenue recognized as collaboration revenue between the license and the services. This allocation is based upon the relative selling price of each deliverable. For the three and nine month periods ended September 30, 2013, license revenue was approximately $13.1 million and $37.7 million, respectively, while research and development services were approximately $3.4 million and $9.8 million, respectively, of the collaboration revenue.
	The collaboration arrangement with Merck includes milestone payments of approximately $880.0 million. These milestones consist of development milestones of approximately $380.0 million and sales-based milestones of approximately $500.0 million. The development milestones range from $5.0 million to $45.0 million and are based on the commencement of a new phase of clinical trials for specific indications, filing for approval in the U.S. or major countries in Europe for specific indications and approval in the U.S. and other major countries. The Company evaluated each of these milestone payments and believes that all but one of the milestones are substantive as there is substantial performance risk that must occur in order for them to be met as they must complete additional clinical trials which show a positive outcome or receive approval from a regulatory authority and would be commensurate with the enhancement of value of the underlying intellectual property. The non-substantive milestone is $5.0 million and was received in the fourth quarter of 2012.  The milestone payment of $5.0 is being combined with the other consideration received in the arrangement, being the license and research and development reimbursements, and under the cumulative catch-up approach will be recognized on a straight-line basis during the performance period. The $500.0 million of sales-based milestones will occur after development milestones are achieved, and the Company will account for these in the same manner as royalties. The sales-based milestones would be achieved if certain sales thresholds are exceeded for worldwide sales of vintafolide and etarfolatide. To date, the products have not been approved and no revenue has been recognized related to the earnings split on U.S sales, development milestones, sales-based milestones or royalties.
	Merck has the right to terminate the collaboration agreement on 90 days notice. Merck and the Company each have the right to terminate the agreement due to the material breach or insolvency of the other party. The Company has the right to terminate the agreement in the event that Merck challenges an Endocyte patent right relating to vintafolide. Upon termination of the agreement, depending upon the circumstances, the parties have varying rights and obligations with respect to the continued development and commercialization of vintafolide and, in the case of termination for cause by Merck, certain royalty obligations and U.S. profit and loss sharing.
	NMP License and Commercialization Agreement
	In August 2013, the Company entered into a license and commercialization agreement with Nihon Medi-Physics Co., Ltd., (“NMP”) that grants NMP the right to develop and commercialize etarfolatide in Japan for use in connection with vintafolide in Japan. The Company received a $1.0 million non-refundable upfront payment, is eligible for up to $4.5 million based on the successful achievement of regulatory goals for etarfolatide in five different cancer indications and is eligible to receive double-digit percentage royalties on sales of etarfolatide in Japan.
	For revenue recognition purposes, the Company viewed the agreement with NMP as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company has identified the deliverables related to the collaboration with NMP, which include the license granted to NMP, as well as the Company’s obligations to provide preclinical and clinical supply of etarfolatide to NMP, to provide rights to NMP if a product is developed that replaces etarfolatide, to provide clinical data to NMP during the contract period and to coordinate development efforts between Merck for vintafolide and NMP for etarfolatide in Japan.  The Company’s deliverables will be accounted for as a single unit of account, therefore the non-refundable upfront payment will be recognized on a straight-line basis over the performance period. This determination was made because the successful development of etarfolatide in Japan requires the ongoing participation by the Company, including coordination with Merck and the development of the related therapeutic drug, vintafolide. The performance period over which the revenue will be recognized continues from the date of execution of the agreement through the end of 2033, the estimated termination date of the contract which is when the Company’s performance obligations will be completed.  Any significant changes in the timing of the performance period could result in a change in the revenue recognition period. The Company had deferred revenue related to the agreement with NMP of approximately $1.0 million at September 30, 2013.
	The arrangement with NMP includes milestone payments of up to approximately $4.5 million and the milestones are based on the commencement of clinical trials in Japan for specific and non-specific indications and filing for regulatory approval in Japan for specific and non-specific indications. The Company evaluated each of these milestone payments and believes that all of the milestones are substantive as there is substantial performance risk that must occur in order for them to be met as they must complete additional clinical trials which show a positive outcome or receive approval from a regulatory authority and would be commensurate with the enhancement of value of the underlying intellectual property. To date, the products have not been approved in Japan and no revenue has been recognized related to the regulatory milestones or royalties.
	NMP has the right to terminate the collaboration agreement on 90 days notice prior to first commercial sale in Japan and six months notice after the first commercial sale in Japan. NMP also has the right to terminate the agreement on six months notice if the Company and or Merck fail to launch vintafolide after receiving regulatory approval in Japan.  NMP and the Company each have the right to terminate the agreement due to the material breach or insolvency of the other party. Upon termination of the agreement depending on the circumstances, the parties have varying rights and obligations with respect to licensing and related regulatory materials and data.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	7. Stockholders’ Equity
	Stock-Based Compensation Plans
	The Company has had stock-based compensation plans since 1997. The awards made under the plans adopted in 1997 and 2007 consisted of stock options. The 2010 Equity Incentive Plan (the “2010 Plan”), which is the only plan under which awards may currently be made, authorizes awards in the form of stock options, stock appreciation rights, restricted stock, RSUs, performance units and performance shares. Awards under the 2010 Plan may be made to employees, directors and certain consultants as determined by the compensation committee of the board of directors. There were 5,195,563 and 6,625,563 shares of common stock authorized and reserved at December 31, 2012 and September 30, 2013 under these plans, respectively.
	Stock Options
	Under the various plans, employees have been granted incentive stock options, while directors and consultants have been granted non-qualified options. The plans allow the holder of an option to purchase common stock at the exercise price, which was at or above the fair value of the Company’s common stock on the date of grant.
	Generally, options granted under the 1997 and 2007 plans in connection with an employee’s commencement of employment vest over a four-year period with one-half of the shares subject to the grant vesting after two years of employment and remaining options vesting monthly over the remainder of the four-year period. Options granted under the 1997 and 2007 plans for performance or promotions vest monthly over a four-year period. Generally, options granted under the 2010 Plan vest annually over a four year period. Unexercised stock options terminate on the tenth anniversary date after the date of grant. The Company recognizes the stock-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period. The Company utilizes a Black-Scholes option-pricing model to estimate the value of stock options. The Black-Scholes model allows the use of a range of assumptions related to volatility, risk-free interest rate, and employee exercise behavior. Prior to 2013, since the Company did not have sufficient history as a publicly traded company to evaluate volatility, the Company used an average of several peer companies’ volatilities to determine a reasonable estimate of volatility. Beginning in 2013, the Company utilizes a combination of peer volatility and company volatility. For purposes of identifying peer companies, the Company considered characteristics such as industry, length of trading history, market capitalization and similar product pipelines.
	Due to the lack of available quarterly data for these peer companies and insufficient history as a public company, the Company is using the “simplified” method for “plain vanilla” options to estimate the expected term of the stock options grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate assumption is derived from the weighted-average yield of a Treasury security with the same term as the expected life of the options, and the dividend yield assumption is based on historical experience and the Company’s estimate of future dividend yields.
	The weighted-average value of the individual options granted during the three and nine months ended September 30, 2012 and 2013 were determined using the following assumptions:
		Three Months								Nine Months
		Ended								Ended
		September 30,								September 30,
		2012				2013				2012			2013
	Weighted-average volatility		90	%			101	%			89.1	%		101	%
	Risk-free interest rate		0.91	%			1.96	%			1.1	%		1.24	%
	Weighted-average expected life (in years)		6.2				6.3				6.2			6.6
	Dividend yield		0	%			0	%			0	%		0	%
	The Company’s stock option activity and related information during the nine months ended September 30, 2013 are summarized as follows:
		Options			Weighted-			Weighted-			Aggregate
					Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price			Contractual
								Term
								(In Years)
	Outstanding at January 1, 2013		3,879,239		$	4.96
	Granted during period		1,140,587			9.85
	Exercised during period		-52,289			2.33
	Expired during period		-
	Forfeited during period		-4,650			3.49
	Outstanding at March 31, 2013		4,962,887		$	6.12			7.9		$	31,462,157
	Exercisable at March 31, 2013		1,966,154		$	3.87			6.05		$	16,884,789
	Outstanding at April 1, 2013		4,962,887
	Granted during period		216,950			12.97
	Exercised during period		-51,778			3.5
	Expired during period		-
	Forfeited during period		-
	Outstanding at June 30, 2013		5,128,059		$	6.43			7.75		$	34,369,209
	Exercisable at June 30, 2013		2,215,185			4.43			6.09			19,277,790
	Outstanding at July 1, 2013		5,128,059
	Granted during period		98,425			16.78
	Exercised during period		-68,517			4.51
	Expired during period		-
	Forfeited during period		-
	Outstanding at September 30, 2013		5,157,967			6.66			7.57			34,783,085
	Exercisable at September 30, 2013		2,248,686		$	4.56			5.94		$	19,720,718
	As of September 30, 2013, the total remaining unrecognized compensation cost related to stock options was $15.9 million which is being amortized over the remaining requisite service period. The expense is expected to be recognized over a weighted average period of 1.9 years.
	Restricted Stock Units
	In May 2011, the Company adopted and granted awards under a new performance-based RSU program (the “2011 RSU Program”) under the Company’s 2010 Plan. Each unit represents one share of the Company’s common stock. The RSUs will be earned, in whole or in part, based on performance and service conditions. The performance condition is based upon whether the Company receives regulatory approval to sell a therapeutic product, and the awards include a target number of RSUs that will vest upon a first commercial approval, and a maximum number of RSUs that will vest upon a second commercial approval. The RSUs will vest fifty percent based on the performance condition of commercial approval and fifty percent one year thereafter to fulfill the service condition, which requires the employee to remain employed by the Company.
	As of September 30, 2013, the Company had 271,062 RSU awards outstanding. The unrecorded stock compensation expense is based on number of units granted, less estimated forfeitures based on the Company’s historical forfeiture rate of 6.49%, and the closing market price of the Company’s common stock at the grant date. As of September 30, 2013, the performance condition of obtaining regulatory approval had not been achieved, therefore, no vesting had occurred. The awards are being accounted for under ASC 718, and compensation expense is to be recorded if the Company determines that it is probable that the performance conditions will be achieved. As of September 30, 2013, it was not probable that the performance conditions will be achieved, therefore, no compensation expense related to the RSUs was recorded for the quarter ended September 30, 2013. Unrecorded compensation expense for the 2011 RSU Program as of September 30, 2013 was $2.7 million.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	8. Income Taxes
	The Company accounts for income taxes under the liability method in accordance with the provisions of ASC Topic 740, Income Taxes. The Company recognizes future tax benefits, such as net operating losses, to the extent those benefits are expected to be realized in future periods. Due to uncertainty surrounding the realization of its deferred tax assets, the Company has recorded an equal and offsetting valuation allowance against its net deferred tax assets. The Company experienced a change in ownership as defined under Section 382 of the U.S. Internal Revenue Code in August 2011. As a result, the future use of its net operating losses and credit equivalents is currently limited to approximately $94.2 million for 2013, $39.0 million for each of the years 2014 and 2015, $29.7 million for 2016 and $16.8 million for 2017. Any available but unused amounts will become available for use in all successive years.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated. The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2013 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission.
Segment Reporting, Policy [Policy Text Block]	'
	Segment Information
	Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company is performing clinical trials globally and has established subsidiaries in The Netherlands and Switzerland to assist in the administration of pending applications with the EMA and pre-commercial planning activities in Europe. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager.
Investment, Policy [Policy Text Block]	'
	Investments
	Investments consist primarily of investments in U.S. Treasuries, U.S. Government agency obligations and corporate debt securities, which could also include commercial paper, that are maintained by an investment manager. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, Investments — Debt and Equity Securities (“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expense over the term of the security.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605, Revenue Recognition (“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25, Multiple-Element Arrangements. Effective January 1, 2011, the Company adopted an accounting standard update that amends the guidance on accounting for arrangements with multiple deliverables. Pursuant to the new standard, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables.
	Upfront payments for licensing the Company's intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue in the balance sheet and are recognized in a manner consistent with the final deliverable. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered.
	In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred.
	Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e. not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone.
	Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company's products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and the collaborator will share profit, the revenue will be recorded in the period earned.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expenses
	Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging diagnostics and include salaries, supplies, and expenses for clinical trials. The Company records accruals for clinical trial expenses based on the estimated amount of work completed. The Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations.
	Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20, Research and Development Arrangements. Upfront payments made in connection with business development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development and are expensed over the service period based upon the level of services provided. As of September 30, 2013, the Company had approximately $3.2 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	The Company accounts for its stock options pursuant to ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the recognition of the fair value or calculated value for nonpublic entities, of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted to employees at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant. The Company has issued restricted stock units (“RSUs”) for which stock-based compensation expense will be recognized when the Company determines it is probable that the performance conditions will be achieved. The Company used the calculated value to measure its stock-based compensation prior to its initial public offering. The Company recognizes compensation cost based on the grant-date value estimated in accordance with the provisions of ASC 718.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss Per Share
	Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants and RSUs are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.
	The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net loss per share computations. The calculation below provides net loss, weighted-average common shares outstanding, and the resultant net loss per share on both a basic and diluted basis for the three and nine months ended September 30, 2012 and 2013.
	Historical net loss per share
		Three Months Ended September 30,					Nine Months Ended September 30,
		2012			2013		2012		2013
	Numerator:
	Net loss	$	-1,239,366		$	-3,041,158	$	-16,443,164	$	-15,130,305
	Denominator:
	Weighted-average common shares outstanding		35,881,112			36,077,440		35,841,116		36,000,242
	Basic and diluted net loss per share	$	-0.03		$	-0.08	$	-0.46	$	-0.42
	Common stock equivalents
	As of September 30, 2012 and 2013, the following number of potential common stock equivalents were outstanding:
		As of September 30,
		2012		2013
	Outstanding common stock options	3,876,968		5,157,967
	Outstanding warrants	133,968		69,294
	Outstanding RSUs	273,988		271,062
	Total	4,284,924		5,498,323
	These common stock equivalents were excluded from the determination of diluted net loss per share due to their anti-dilutive effect on earnings.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]	'
	The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net loss per share computations. The calculation below provides net loss, weighted-average common shares outstanding, and the resultant net loss per share on both a basic and diluted basis for the three and nine months ended September 30, 2012 and 2013.
	Historical net loss per share
		Three Months Ended September 30,					Nine Months Ended September 30,
		2012			2013		2012		2013
	Numerator:
	Net loss	$	-1,239,366		$	-3,041,158	$	-16,443,164	$	-15,130,305
	Denominator:
	Weighted-average common shares outstanding		35,881,112			36,077,440		35,841,116		36,000,242
	Basic and diluted net loss per share	$	-0.03		$	-0.08	$	-0.46	$	-0.42
Schedule of Weighted Average Number of Shares [Table Text Block]	'
	As of September 30, 2012 and 2013, the following number of potential common stock equivalents were outstanding:
		As of September 30,
		2012		2013
	Outstanding common stock options	3,876,968		5,157,967
	Outstanding warrants	133,968		69,294
	Outstanding RSUs	273,988		271,062
	Total	4,284,924		5,498,323

Other_Comprehensive_Income_Los1

Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2013
Other Comprehensive Income (Loss), Tax [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	The accumulated balances related to each component of other comprehensive income (loss) were as follows:
		Foreign Currency		Unrealized Net		Accumulated
		Translation Gains		Gains (Losses)		Other
		(Losses)		on		Comprehensive
				Securities		Gains
						(Losses)
	Balance at December 31, 2012	$	-5,011	$	77,760	$	72,749
	Unrealized loss		-17,831		-29,047		-46,878
	Net amount reclassified to net loss		—		-4,916		-4,916
	Other comprehensive loss		-17,831		-33,963		-51,794
	Balance at September 30, 2013	$	-22,842	$	43,797	$	-20,955
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	'
	Reclassifications Out of Accumulated Other Comprehensive Loss
	For the Nine Months Ended September 30, 2013
		Amount
		Reclassified from
		Accumulated
		Other
		Comprehensive
		Loss
	Details about Accumulated Other	Three		Nine Months		Affected Line Item in the
	Comprehensive Loss Components	Months		Ended		Condensed Consolidated
		Ended		September		Statements of Operations and
		September		30, 2013		Comprehensive Loss
		30, 2013
	Unrealized Net Gains on Securities	$	536	$	4,916	Other income (expense)
	Total Reclassifications for the period	$	536	$	4,916

Investments_Tables

Investments (Tables)	9 Months Ended
	Sep. 30, 2013
Investments, Debt and Equity Securities [Abstract]	'
Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]	'
	The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2012:
	Description	Cost		Level 1		Level 2		Fair Value
								(Carrying
								Value)
	Cash
	Cash	$	5,227,208	$	5,227,208	$	—	$	5,227,208
	Cash equivalents
	Money market funds		28,769,658		28,769,658		—		28,769,658
	Cash and cash equivalents	$	33,996,866	$	33,996,866	$	—	$	33,996,866
	Short-term investments (due within 1 year)
	U.S. government treasury obligations	$	10,049,323	$	10,053,393	$	—	$	10,053,393
	U.S. government agency obligations		89,824,358		89,847,365		—		89,847,365
	Corporate obligations		41,905,867		—		41,940,065		41,940,065
	Total Short-term investments	$	141,779,548	$	99,900,758	$	41,940,065	$	141,840,823
	Long-term investments (due after 1 year through 2 years)
	U.S. government treasury obligations	$	5,024,697	$	5,030,699	$	—	$	5,030,699
	U.S. government agency obligations		17,455,606		17,463,067		—		17,463,067
	Corporate obligations		3,043,860		—		3,046,883		3,046,883
	Total Long-term investments	$	25,524,163	$	22,493,766	$	3,046,883	$	25,540,649
	The following table summarizes the fair value of cash and cash equivalents and investments as of September 30, 2013:
	Description	Cost		Level 1		Level 2		Fair Value
								(Carrying
								Value)
	Cash
	Cash	$	10,416,113	$	10,416,113	$	—	$	10,416,113
	Cash equivalents
	Money market funds		40,829,806		40,829,806		—		40,829,806
	Cash and cash equivalents	$	51,245,919	$	51,245,919	$	—	$	51,245,919
	Short-term investments (due within 1 year)
	U.S. government treasury obligations	$	15,023,419		15,035,200		—		15,035,200
	U.S. government agency obligations		16,171,793		16,184,311		—		16,184,311
	Corporate obligations		28,678,553		—		28,689,238		28,689,238
	Total Short-term investments	$	59,873,765		31,219,511		28,689,238		59,908,749
	Long-term investments (due after 1 year through 2 years)
	U.S. government treasury obligations	$	—		—		—		—
	U.S. government agency obligations		35,116,060		35,131,581		—		35,131,581
	Corporate obligations		12,912,265		—		12,905,563		12,905,563
	Total Long-term investments	$	48,028,325		35,131,581		12,905,563		48,037,144

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The weighted-average value of the individual options granted during the three and nine months ended September 30, 2012 and 2013 were determined using the following assumptions:
		Three Months								Nine Months
		Ended								Ended
		September 30,								September 30,
		2012				2013				2012			2013
	Weighted-average volatility		90	%			101	%			89.1	%		101	%
	Risk-free interest rate		0.91	%			1.96	%			1.1	%		1.24	%
	Weighted-average expected life (in years)		6.2				6.3				6.2			6.6
	Dividend yield		0	%			0	%			0	%		0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The Company’s stock option activity and related information during the nine months ended September 30, 2013 are summarized as follows:
		Options			Weighted-			Weighted-			Aggregate
					Average			Average			Intrinsic
					Exercise			Remaining			Value
					Price			Contractual
								Term
								(In Years)
	Outstanding at January 1, 2013		3,879,239		$	4.96
	Granted during period		1,140,587			9.85
	Exercised during period		-52,289			2.33
	Expired during period		-
	Forfeited during period		-4,650			3.49
	Outstanding at March 31, 2013		4,962,887		$	6.12			7.9		$	31,462,157
	Exercisable at March 31, 2013		1,966,154		$	3.87			6.05		$	16,884,789
	Outstanding at April 1, 2013		4,962,887
	Granted during period		216,950			12.97
	Exercised during period		-51,778			3.5
	Expired during period		-
	Forfeited during period		-
	Outstanding at June 30, 2013		5,128,059		$	6.43			7.75		$	34,369,209
	Exercisable at June 30, 2013		2,215,185			4.43			6.09			19,277,790
	Outstanding at July 1, 2013		5,128,059
	Granted during period		98,425			16.78
	Exercised during period		-68,517			4.51
	Expired during period		-
	Forfeited during period		-
	Outstanding at September 30, 2013		5,157,967			6.66			7.57			34,783,085
	Exercisable at September 30, 2013		2,248,686		$	4.56			5.94		$	19,720,718

Significant_Accounting_Policie3

Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net loss	($3,041,158)	($1,239,366)	($15,130,305)	($16,443,164)
Denominator:	'	'	'	'
Weighted-average common shares outstanding (in shares)	36,077,440	35,881,112	36,000,242	35,841,116
Basic and diluted net loss per share (in dollars per share)	($0.08)	($0.03)	($0.42)	($0.46)

Significant_Accounting_Policie4

Significant Accounting Policies (Details 1)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Potential Common Stock Equivalents Outstanding	5,498,323	4,284,924
Outstanding Common Stock Options [Member]	'	'
Potential Common Stock Equivalents Outstanding	5,157,967	3,876,968
Outstanding RSUs [Member]	'	'
Potential Common Stock Equivalents Outstanding	271,062	273,988
Outstanding warrants [Member]	'	'
Potential Common Stock Equivalents Outstanding	69,294	133,968

Significant_Accounting_Policie5

Significant Accounting Policies (Details Textual) (USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
Prepaid Expense and Other Assets, Noncurrent	$3.20

Other_Comprehensive_Income_Los2

Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Foreign Currency Translation Gains (Losses), Beginning balance	'	'	($5,011)	'
Unrealized loss on foreign currency translation	3,419	1,544	-17,831	2,624
Foreign Currency Translation Gains (Losses), Net amount reclassified to net loss	'	'	0	'
Foreign Currency Translation Gains (Losses), Other comprehensive income (loss)	'	'	-17,831	'
Foreign Currency Translation Gains (Losses), Ending balance	-22,842	'	-22,842	'
Unrealized Net Gains (Losses) on Securities, Beginning balance	'	'	77,760	'
Unrealized Net Gains (Losses) on Securities, Unrealized gain (loss)	'	'	-29,047	'
Unrealized Net Gains (Losses) on Securities, Net amount reclassified to net loss	-536	'	-4,916	'
Unrealized Net Gains (Losses) on Securities, Other comprehensive income (loss)	105,088	114,855	-33,963	70,324
Unrealized Net Gains (Losses) on Securities, Ending balance	43,797	'	43,797	'
Accumulated Other Comprehensive Gains (Losses), Beginning balance	'	'	72,749	'
Accumulated Other Comprehensive Gains (Losses), Unrealized gain (loss)	'	'	-46,878	'
Accumulated Other Comprehensive Gains (Losses), Net amount reclassified to net loss	'	'	-4,916	'
Accumulated Other Comprehensive Gains (Losses), Other comprehensive income (loss)	'	'	-51,794	'
Accumulated Other Comprehensive Gains (Losses), Ending balance	$20,955	'	$20,955	'

Other_Comprehensive_Income_Los3

Other Comprehensive Income (Loss) (Details 1) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Amount Reclassified from Accumulated Other Comprehensive Loss, Unrealized Net Gains (Losses) on Securities	$536	$4,916
Other Income (Expense) [Member]	'	'
Amount Reclassified from Accumulated Other Comprehensive Loss, Unrealized Net Gains (Losses) on Securities	$536	$4,916

Investments_Details

Investments (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Cash	'	'	'	'
Cash	$10,416,113	$5,227,208	'	'
Cash equivalents	'	'	'	'
Money market funds	40,829,806	28,769,658	'	'
Cash and cash equivalents	51,245,919	33,996,866	36,728,677	61,352,483
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	59,908,749	141,840,823	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	48,037,144	25,540,649	'	'
US Treasury Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	15,035,200	10,053,393	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	0	5,030,699	'	'
US Government Agencies Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	16,184,311	89,847,365	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	35,131,581	17,463,067	'	'
Corporate Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	28,689,238	41,940,065	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	12,905,563	3,046,883	'	'
Fair Value, Inputs, Level 1 [Member]	'	'	'	'
Cash	'	'	'	'
Cash	10,416,113	5,227,208	'	'
Cash equivalents	'	'	'	'
Money market funds	40,829,806	28,769,658	'	'
Cash and cash equivalents	51,245,919	33,996,866	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	31,219,511	99,900,758	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	35,131,581	22,493,766	'	'
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	15,035,200	10,053,393	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	0	5,030,699	'	'
Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	16,184,311	89,847,365	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	35,131,581	17,463,067	'	'
Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	0	0	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	0	0	'	'
Fair Value, Inputs, Level 2 [Member]	'	'	'	'
Cash	'	'	'	'
Cash	0	0	'	'
Cash equivalents	'	'	'	'
Money market funds	0	0	'	'
Cash and cash equivalents	0	0	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	28,689,238	41,940,065	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	12,905,563	3,046,883	'	'
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	0	0	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	0	0	'	'
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	0	0	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	0	0	'	'
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	28,689,238	41,940,065	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	12,905,563	3,046,883	'	'
Cost [Member]	'	'	'	'
Cash	'	'	'	'
Cash	10,416,113	5,227,208	'	'
Cash equivalents	'	'	'	'
Money market funds	40,829,806	28,769,658	'	'
Cash and cash equivalents	51,245,919	33,996,866	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	59,873,765	141,779,548	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	48,028,325	25,524,163	'	'
Cost [Member] | US Treasury Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	15,023,419	10,049,323	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	0	5,024,697	'	'
Cost [Member] | US Government Agencies Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	16,171,793	89,824,358	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	35,116,060	17,455,606	'	'
Cost [Member] | Corporate Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Total Short-term investments	28,678,553	41,905,867	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total Long-term investments	$12,912,265	$3,043,860	'	'

Investments_Details_Textual

Investments (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Unrealized Gain on Securities	$72,526	$71,936
Unrealized Loss on Securities	$28,729	$2,158

Collaborations_Details_Textual

Collaborations (Details Textual) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

Apr. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Aug. 31, 2013

Sep. 30, 2013

Apr. 30, 2012

Apr. 30, 2012

Apr. 30, 2012

Apr. 30, 2012

Apr. 30, 2012

NMP [Member]

NMP [Member]

Development Milestones [Member]

Sales Based Milestones [Member]

Non Substantive Milestone [Member]

Maximum [Member]

Minimum [Member]

Development Milestones [Member]

Development Milestones [Member]

Payments to Acquire in Process Research and Development

$120,000,000

'

'

'

'

'

'

'

'

'

'

'

Non-refundable Upfront Payments Received

120,000,000

'

'

'

'

1,000,000

'

'

'

5,000,000

'

'

Collaboration Revenue

'

16,599,294

12,414,684

47,596,716

20,227,649

'

'

'

'

'

'

'

Deferred Revenue

'

73,600,000

'

73,600,000

'

'

1,000,000

'

'

'

'

'

Potential Milestone Payments

880,000,000

'

'

'

'

4,500,000

'

380,000,000

500,000,000

'

45,000,000

5,000,000

Maximum Eligible Amount for Milestone Payments

875,000,000

'

'

'

'

'

'

'

'

'

'

'

License Costs

'

13,100,000

'

37,700,000

'

'

'

'

'

'

'

'

License and Services Revenue

'

$3,400,000

'

$9,800,000

'

'

'

'

'

'

'

'

Stockholders_Equity_Details

Stockholders' Equity (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Weighted-average volatility	101.00%	90.00%	101.00%	89.10%
Risk-free interest rate	1.96%	0.91%	1.24%	1.10%
Weighted-average expected life (in years)	'6 years 3 months 18 days	'6 years 2 months 12 days	'6 years 7 months 6 days	'6 years 2 months 12 days
Dividend yield	0.00%	0.00%	0.00%	0.00%

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Options, Outstanding, Beginning Balance	5,128,059	4,962,887	3,879,239
Options, Granted during period	98,425	216,950	1,140,587
Options, Exercised during period	-68,517	-51,778	-52,289
Options, Expired during period	0	0	0
Options, Forfeited during period	0	0	-4,650
Options, Outstanding, Ending Balance	5,157,967	5,128,059	4,962,887
Options, Exercisable	2,248,686	2,215,185	1,966,154
Weighted Average Exercise Price, Outstanding, Beginning Balance	$6.43	$6.12	$4.96
Weighted Average Exercise Price, Granted during period	$16.78	$12.97	$9.85
Weighted Average Exercise Price, Exercised during period	$4.51	$3.50	$2.33
Weighted Average Exercise Price, Forfeited during period	'	'	$3.49
Weighted Average Exercise Price, Outstanding Ending Balance	$6.66	$6.43	$6.12
Weighted Average Exercise Price, Exercisable	$4.56	$4.43	$3.87
Weighted Average Remaining Contractual Term, Outstanding, Ending Balance	'7 years 6 months 25 days	'7 years 9 months	'7 years 10 months 24 days
Weighted Average Remaining Contractual Term, Exercisable	'5 years 11 months 8 days	'6 years 1 month 2 days	'6 years 18 days
Aggregate Intrinsic Value, Outstanding, Ending Balance	$34,783,085	$34,369,209	$31,462,157
Aggregate Intrinsic Value, Exercisable	$19,720,718	$19,277,790	$16,884,789

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
Common Stock, Shares Authorized	100,000,000	'	'	100,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	5,157,967	5,128,059	4,962,887	3,879,239
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'1 year 10 months 24 days	'	'	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	2.7	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	271,062	'	'	'
Percentage of Historical Forfeiture	6.49%	'	'	'
Equity Incentive Plan 2010 [Member]	'	'	'	'
Common Stock, Shares Authorized	6,625,563	'	'	5,195,563
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	15.9	'	'	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
For 2013 [Member]	'
Operating Loss Carryforwards	$94.20
For Each of 2014 and 2015 [Member]	'
Operating Loss Carryforwards	39
For 2016 [Member]	'
Operating Loss Carryforwards	29.7
For 2017 [Member]	'
Operating Loss Carryforwards	$16.80